2,963 research outputs found
Identification of hereditary cancer in the general population: development and validation of a screening questionnaire for obtaining the family history of cancer
One of the challenges for Latin American countries is to include in their healthcare
systems technologies that can be applied to hereditary cancer detection
and management. The aim of the study is to create and validate a questionnaire
to identify individuals with possible risk for hereditary cancer predisposition
syndromes (HCPS), using different strategies in a Cancer Prevention Service in
Brazil. The primary screening questionnaire (PSQ) was developed to identify
families at-risk for HCPS. The PSQ was validated using discrimination measures,
and the reproducibility was estimated through kappa coefficient. Patients with
at least one affirmative answer had the pedigree drawn using three alternative
interview approaches: in-person, by telephone, or letter. Validation of these
approaches was done. Kappa and intraclass correlation coefficients were used
to analyze dataâs reproducibility considering the presence of clinical criteria for
HCPS. The PSQ was applied to a convenience sample of 20,000 women of
which 3121 (15.6%) answered at least one affirmative question and 1938 had
their pedigrees drawn. The PSQ showed sensitivity and specificity scores of
94.4% and 75%, respectively, and a kappa of 0.64. The strategies for pedigree
drawing had reproducibility coefficients of 0.976 and 0.850 for the telephone
and letter approaches, respectively. Pedigree analysis allowed us to identify 465
individuals (24.0%) fulfilling at least one clinical criterion for HCPS. The PSQ
fulfills its function, allowing the identification of HCPS at-risk families. The
use of alternative screening methods may reduce the number of excluded at-risk
individuals/families who live in locations where oncogenetic services are not
established.Research supported by Barretos Cancer
Hospital. EIP has a grant from FAPESP
(FAPESP, SP, Brazil, #2013/24633-2). N
Campacci is supported by a PhD fellowship
from FAPESP (FAPESP, SP, Brazil,
#2015/02444-9).info:eu-repo/semantics/publishedVersio
The R136 star cluster hosts several stars whose individual masses greatly exceed the accepted 150 Msun stellar mass limit
Spectroscopic analyses of H-rich WN5-6 stars within the young star clusters
NGC 3603 and R136 are presented, using archival HST & VLT spectroscopy, & high
spatial resolution near-IR photometry. We derive high T* for the WN stars in
NGC 3603 (T*~42+/-2 kK) & R136 (T*~53+/-3 kK) plus clumping-corrected dM/dt ~
2-5x10^-5 Msun/yr which closely agree with theoretical predictions. These stars
make a disproportionate contribution to the global budget of their host
clusters. R136a1 alone supplies ~7% of N(LyC) of the entire 30 Dor region.
Comparisons with stellar models calculated for the main-sequence evolution of
85-500 Msun suggest ages of ~1.5 Myr & M_init in the range 105 - 170 Msun for 3
systems in NGC 3603, plus 165-320 Msun for 4 stars in R136. Our high stellar
masses are supported by dynamical mass determinations for the components of NGC
3603 A1. We consider the predicted L_X of the R136 stars if they were close,
colliding wind binaries. R136c is consistent with a colliding wind binary
system. However, short period, colliding wind systems are excluded for R136a WN
stars if mass ratios are of order unity. Widely separated systems would have
been expected to harden owing to early dynamical encounters with other massive
stars in such a dense environment. From simulated star clusters, whose
constituents are randomly sampled from the Kroupa IMF, both clusters are
consistent with a tentative upper mass limit of ~300 Msun. The Arches cluster
is either too old, exhibits a deficiency of very massive stars, or more likely
stellar masses have been underestimated - M_init for the most luminous stars in
the Arches cluster approach 200 Msun according to contemporary stellar &
photometric results. The potential for stars greatly exceeding 150 Msun within
metal-poor galaxies suggests that such pair-instability SNe could occur within
the local universe, as has been claimed for SN 2007bi (abridged).Comment: 20 pages, 14 figures, accepted for MNRAS. Version with higher
resolution figures is available from
http://pacrowther.staff.shef.ac.uk/R136.pdf See also
http://www.eso.org/public/news/eso1030/ from Wed 21 from noon (CEST
Opportunistic screening for skin cancer using a mobile unit in Brazil
Abstract
Background
Skin cancer is the most common malignancy in the white population worldwide. In Brazil, the National Cancer Institute (INCA) estimates that in 2010 there will be 119,780 and 5,930 new cases of non-melanoma skin cancer and melanoma, respectively. The aim of this study was to evaluate the use of a mobile unit in the diagnosis and treatment of skin cancer in several poor regions of Brazil.
Methods
The diagnosis of skin cancer was accomplished through active medical screening in the prevention Mobile Unit (MU) of Barretos Cancer Hospital (BCH). The study population consisted of patients examined in the MU between 2004 and 2007, and their suspicious lesions were subjected to histopathological evaluation. Data were collected prospectively from standardized forms and analyzed.
Results
During the screening, 17,857 consultations were carried out. A total of 2012 (11.2%) cases of skin cancer were diagnosed. The predominant histological type reported was basal cell carcinoma (n = 1,642 or 81.6%), followed by squamous cell carcinoma (n = 303 or 15.1%), Bowen's disease (n = 25 or 1.2%), malignant melanoma (n = 23 or 1.1%), basosquamous cell carcinoma (n = 3 or 0.1%), miscellaneous lesions (12 or 0.6%), and metatypical carcinoma (n = 4 or 0.2%). Only 0.6% of lesions were stage III. There were no stage IV non-melanoma skin lesions, as well as no melanomas stages III and IV, found.
Conclusions
It was observed that the MU can be a useful tool for early skin cancer diagnosis and treatment. This program probably is important, especially in developing countries with inadequate public health systems and social inequality
Pathway and network analysis of more than 2500 whole cancer genomes
The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of non-coding mutations across 2583 whole cancer genomes from 27 tumor types compiled by the ICGC/TCGA PCAWG project that was motivated by the success of pathway and network analyses in prioritizing rare mutations in protein-coding genes. While few non-coding genomic elements are recurrently mutated in this cohort, we identify 93 genes harboring non-coding mutations that cluster into several modules of interacting proteins. Among these are promoter mutations associated with reduced mRNA expression in TP53, TLE4, and TCF4. We find that biological processes had variable proportions of coding and non-coding mutations, with chromatin remodeling and proliferation pathways altered primarily by coding mutations, while developmental pathways, including Wnt and Notch, altered by both coding and non-coding mutations. RNA splicing is primarily altered by non-coding mutations in this cohort, and samples containing non-coding mutations in well-known RNA splicing factors exhibit similar gene expression signatures as samples with coding mutations in these genes. These analyses contribute a new repertoire of possible cancer genes and mechanisms that are altered by non-coding mutations and offer insights into additional cancer vulnerabilities that can be investigated for potential therapeutic treatments
Association of Killer Cell Immunoglobulin-Like Receptor Genes with Hodgkin's Lymphoma in a Familial Study
BACKGROUND: Epstein-Barr virus (EBV) is the major environmental factor associated with Hodgkin's lymphoma (HL), a common lymphoma in young adults. Natural killer (NK) cells are key actors of the innate immune response against viruses. The regulation of NK cell function involves activating and inhibitory Killer cell Immunoglobulin-like receptors (KIRs), which are expressed in variable numbers on NK cells. Various viral and virus-related malignant disorders have been associated with the presence/absence of certain KIR genes in case/control studies. We investigated the role of the KIR cluster in HL in a family-based association study. METHODOLOGY: We included 90 families with 90 HL index cases (age 16â35 years) and 255 first-degree relatives (parents and siblings). We developed a procedure for reconstructing full genotypic information (number of gene copies) at each KIR locus from the standard KIR gene content. Out of the 90 collected families, 84 were informative and suitable for further analysis. An association study was then carried out with specific family-based analysis methods on these 84 families. PRINCIPAL FINDINGS: Five KIR genes in strong linkage disequilibrium were found significantly associated with HL. Refined haplotype analysis showed that the association was supported by a dominant protective effect of KIR3DS1 and/or KIR2DS1, both of which are activating receptors. The odds ratios for developing HL in subjects with at least one copy of KIR3DS1 or KIR2DS1 with respect to subjects with neither of these genes were 0.44[95% confidence interval 0.23â0.85] and 0.42[0.21â0.85], respectively. No significant association was found in a tentative replication case/control study of 68 HL cases (age 18â71 years). In the familial study, the protective effect of KIR3DS1/KIR2DS1 tended to be stronger in HL patients with detectable EBV in blood or tumour cells. CONCLUSIONS: This work defines a template for family-based association studies based on full genotypic information for the KIR cluster, and provides the first evidence that activating KIRs can have a protective role in HL
Recommended from our members
The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism.
International audienceAlthough multiple reports show that defective genetic networks underlie the aetiology of autism, few have translated into pharmacotherapeutic opportunities. Since drugs compete with endogenous small molecules for protein binding, many successful drugs target large gene families with multiple drug binding sites. Here we search for defective gene family interaction networks (GFINs) in 6,742 patients with the ASDs relative to 12,544 neurologically normal controls, to find potentially druggable genetic targets. We find significant enrichment of structural defects (Pâ€2.40E-09, 1.8-fold enrichment) in the metabotropic glutamate receptor (GRM) GFIN, previously observed to impact attention deficit hyperactivity disorder (ADHD) and schizophrenia. Also, the MXD-MYC-MAX network of genes, previously implicated in cancer, is significantly enriched (Pâ€3.83E-23, 2.5-fold enrichment), as is the calmodulin 1 (CALM1) gene interaction network (Pâ€4.16E-04, 14.4-fold enrichment), which regulates voltage-independent calcium-activated action potentials at the neuronal synapse. We find that multiple defective gene family interactions underlie autism, presenting new translational opportunities to explore for therapeutic interventions
The 16th Data Release of the Sloan Digital Sky Surveys : First Release from the APOGEE-2 Southern Survey and Full Release of eBOSS Spectra
This paper documents the 16th data release (DR16) from the Sloan Digital Sky Surveys (SDSS), the fourth and penultimate from the fourth phase (SDSS-IV). This is the first release of data from the Southern Hemisphere survey of the Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2); new data from APOGEE-2 North are also included. DR16 is also notable as the final data release for the main cosmological program of the Extended Baryon Oscillation Spectroscopic Survey (eBOSS), and all raw and reduced spectra from that project are released here. DR16 also includes all the data from the Time Domain Spectroscopic Survey and new data from the SPectroscopic IDentification of ERosita Survey programs, both of which were co-observed on eBOSS plates. DR16 has no new data from the Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey (or the MaNGA Stellar Library "MaStar"). We also preview future SDSS-V operations (due to start in 2020), and summarize plans for the final SDSS-IV data release (DR17).Peer reviewe
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population
- âŠ